Trial Profile
Study of Radium-223 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Dec 2015 New trial record